Published in Calcif Tissue Int on January 01, 1981
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Matrix-embedded cells control osteoclast formation. Nat Med (2011) 5.77
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest (1992) 3.40
Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One (2008) 2.96
Osteopontin--a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A (1990) 2.90
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol (1996) 2.36
Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther (2007) 2.30
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol (2000) 2.12
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells. J Clin Invest (1983) 1.84
Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol (2000) 1.77
Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation. Am J Pathol (1997) 1.67
Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J Exp Med (1993) 1.63
Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci U S A (1998) 1.63
Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med (1995) 1.60
Connexin43 mediates direct intercellular communication in human osteoblastic cell networks. J Clin Invest (1993) 1.59
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest (1993) 1.58
Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep (2014) 1.57
In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. J Exp Med (1982) 1.56
Parathyroid hormone-related protein is required for tooth eruption. Proc Natl Acad Sci U S A (1998) 1.52
The cellular basis of bone remodeling: the quantum concept reexamined in light of recent advances in the cell biology of bone. Calcif Tissue Int (1984) 1.50
The pathobiology of the osteoclast. J Clin Pathol (1985) 1.48
Control of RANKL gene expression. Bone (2009) 1.47
Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. Bone (2012) 1.40
Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A (1996) 1.37
Osteocyte control of osteoclastogenesis. Bone (2012) 1.36
Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res (2012) 1.29
1,25-Dihydroxyvitamin D3 causes formation of multinucleated cells with several osteoclast characteristics in cultures of primate marrow. Proc Natl Acad Sci U S A (1985) 1.27
The Interplay between the bone and the immune system. Clin Dev Immunol (2013) 1.26
Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline marrow mononuclear cells. J Cell Biol (1984) 1.22
Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000 (2014) 1.20
Recruitment of osteoclast precursors by purified bone matrix constituents. J Cell Biol (1982) 1.18
The critical role of IL-34 in osteoclastogenesis. PLoS One (2011) 1.14
Enhanced osteoblast proliferation and collagen gene expression by estradiol. Proc Natl Acad Sci U S A (1988) 1.11
Parathyroid hormone modulates transforming growth factor beta activity and binding in osteoblast-enriched cell cultures from fetal rat parietal bone. Proc Natl Acad Sci U S A (1988) 1.09
Study of the cell biology and biochemistry of cherubism. J Clin Pathol (1998) 1.09
Vitamin D and bone. Curr Osteoporos Rep (2012) 1.08
Oral inflammatory diseases and systemic inflammation: role of the macrophage. Front Immunol (2012) 1.07
Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest (1994) 1.04
Phorbol ester induced osteoclast-like differentiation of a novel human leukemic cell line (FLG 29.1). J Cell Biol (1992) 1.02
Historically significant events in the discovery of RANK/RANKL/OPG. World J Orthop (2013) 1.02
Direct extraction and assay of bone tissue collagenase and its relation to parathyroid-hormone-induced bone resorption. Biochem J (1986) 1.00
Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest (1995) 0.98
Osteoclast formation from mononuclear phagocytes: role of bone-forming cells. J Cell Biol (1984) 0.98
Emerging treatments for postmenopausal osteoporosis - focus on denosumab. Clin Interv Aging (2009) 0.98
Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut (2003) 0.98
Overview of osteoporosis. West J Med (1991) 0.97
Bone homeostasis. Proc Natl Acad Sci U S A (1998) 0.95
Mechanisms of osteoclast-dependent bone formation. Bonekey Rep (2013) 0.94
Interleukin-6 attenuates agonist-mediated calcium mobilization in murine osteoblastic cells. J Clin Invest (1994) 0.93
The past, present, and future of bone morphometry: its contribution to an improved understanding of bone biology. J Bone Miner Metab (2005) 0.90
Comparison of postreceptor effects of 1-34 human hypercalcemia factor and 1-34 human parathyroid hormone in rat osteosarcoma cells. J Clin Invest (1988) 0.89
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int (2006) 0.89
Breast Cancer: Rank Ligand Inhibition. Breast Care (Basel) (2010) 0.88
c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis (2003) 0.87
Bone remodeling: new aspects of a key process that controls skeletal maintenance and repair. Osteoporos Int (2004) 0.87
Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86
Human osteoblasts in vitro secrete tissue inhibitor of metalloproteinases and gelatinase but not interstitial collagenase as major cellular products. J Clin Invest (1989) 0.86
Vitamin A effects on UMR 106 osteosarcoma cells are not mediated by specific cytosolic receptors. Biochem J (1985) 0.86
Cloning and characterization of the type I inositol 1,4,5-trisphosphate receptor gene promoter. Regulation by 17beta-estradiol in osteoblasts. J Biol Chem (1997) 0.86
IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1,25 dihydroxyvitamin D3. J Clin Invest (1993) 0.85
Roles of hyaluronan in bone resorption. BMC Musculoskelet Disord (2004) 0.85
Retrovirus-induced osteopetrosis in mice. Ultrastructural evidence of early virus production in osteoblasts and osteocytes. Am J Pathol (1986) 0.85
Understanding the advances in biology of orthodontic tooth movement for improved ortho-perio interdisciplinary approach. J Indian Soc Periodontol (2013) 0.83
Hormones in the coupling of bone resorption and formation. Osteoporos Int (1993) 0.82
Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development. Cell Rep (2015) 0.82
Voltage-gated sodium and calcium currents in rat osteoblasts. J Physiol (1988) 0.81
Effects of neuropeptides and mechanical loading on bone cell resorption in vitro. Int J Mol Sci (2014) 0.81
Identification of a vitamin D-responsive protein on the surface of human osteosarcoma cells. Proc Natl Acad Sci U S A (1989) 0.81
Chick osteocyte-derived protein inhibits osteoclastic bone resorption. Biochem J (1997) 0.80
Molecular cloning and expression of a unique rabbit osteoclastic phosphotyrosyl phosphatase. Biochem J (1996) 0.80
Behaviour of osteoclasts in vitro: contact behaviour of osteoclasts with osteoblast-like cells and networking of osteoclasts for 3D orientation. J Anat (1992) 0.80
Osteoclasts and the resorption of bone by transplanted mammary carcinoma in rats. Br J Cancer (1985) 0.79
Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol (2011) 0.79
Hyperosmotic Stimulus Down-regulates 1alpha, 25-dihydroxyvitamin D(3)-induced Osteoclastogenesis by Suppressing the RANKL Expression in a Co-culture System. Korean J Physiol Pharmacol (2010) 0.79
Induction of osteoclast characteristics in cultured avian blood monocytes; modulation by osteoblasts and 1,25-(OH)2 vitamin D3. Int J Exp Pathol (1995) 0.79
Parathyroid hormone-related protein induces spontaneous osteoclast formation via a paracrine cascade. Proc Natl Acad Sci U S A (2000) 0.78
A coupled mechano-biochemical model for bone adaptation. J Math Biol (2013) 0.77
Effect of parathyroid hormone on phospholipid metabolism in osteoblast-like rat osteogenic sarcoma cells. Biochem J (1986) 0.77
Secretory products of breast cancer cells upregulate hyaluronan production in a human osteoblast cell line. Clin Exp Metastasis (2006) 0.77
Osteoblast-osteoclast interactions. Connect Tissue Res (2017) 0.77
Mouse models in skeletal physiology and osteoporosis: experiences and data on 14,839 cases from the Hamburg Mouse Archives. J Bone Miner Metab (2005) 0.76
Biomarks in secondary osteoporosis. Clin Rheumatol (1989) 0.76
Periodontal Ligament Stem Cells in the Periodontitis Microenvironment Are Sensitive to Static Mechanical Strain. Stem Cells Int (2017) 0.75
Contributions to osteoclast biology from Japan. Proc Jpn Acad Ser B Phys Biol Sci (2008) 0.75
Prostaglandins in pathological bone resorption. Agents Actions (1986) 0.75
Connecting mechanics and bone cell activities in the bone remodeling process: an integrated finite element modeling. Front Bioeng Biotechnol (2014) 0.75
Osteoblast-like cell line maintains in vitro rat peritoneal mast cell viability and functional activity. Immunology (1990) 0.75
[Novel anti-osteoporotic drugs on the horizon]. Z Rheumatol (2016) 0.75
Bone-seeking agents for the treatment of bone disorders. Drug Deliv Transl Res (2017) 0.75
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Therapeutic approaches to bone diseases. Science (2000) 5.60
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med (2000) 5.02
Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A (1990) 4.40
Osteoblastic cells are involved in osteoclast formation. Endocrinology (1988) 4.37
Modulation of osteoclast differentiation. Endocr Rev (1992) 4.27
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J (1994) 3.60
A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis (1999) 2.93
The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology (1989) 2.83
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A (1999) 2.66
Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest (1991) 2.63
Parathyroid hormone-responsive clonal cell lines from rat osteosarcoma. Endocrinology (1980) 2.46
Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone (2002) 2.40
The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med (1984) 2.33
Malignant glaucoma after laser iridotomy. Ophthalmology (1992) 2.28
Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun (1999) 2.28
Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res (1991) 2.26
Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature (2000) 2.13
Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology (1999) 2.11
Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol (1992) 2.09
Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res (1999) 2.06
Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res (1987) 2.03
The hypercalcemia of malignancy: pathogenesis and management. Metabolism (1982) 2.01
Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology (2001) 1.98
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone (2001) 1.94
Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells. J Clin Invest (1983) 1.84
M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ (2003) 1.83
Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy. Br J Haematol (1996) 1.79
Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology (1998) 1.75
A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology (1998) 1.75
PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. J Clin Invest (1998) 1.74
Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest (1986) 1.73
Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem (2005) 1.71
Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int (1999) 1.69
Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone (1999) 1.66
Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology (2001) 1.66
The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study. J Bone Miner Res (1998) 1.65
Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue. Science (1988) 1.64
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology (2000) 1.61
Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res (1990) 1.61
Tissue specificity and developmental expression of rat osteopontin. Biochem Biophys Res Commun (1987) 1.61
Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med (1995) 1.60
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest (1993) 1.58
Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest (1994) 1.57
High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. J Bone Miner Res (1998) 1.56
Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res (1990) 1.54
Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res (1990) 1.52
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science (1983) 1.52
IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol (2001) 1.52
Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res (2001) 1.47
Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? J Bone Joint Surg Br (1981) 1.46
The effect of 1,25(OH)2D3 on alkaline phosphatase in osteoblastic osteosarcoma cells. J Biol Chem (1982) 1.45
Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet (1993) 1.45
Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ (2004) 1.44
Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci (1999) 1.38
Morphological and biochemical characterization of four clonal osteogenic sarcoma cell lines of rat origin. Cancer Res (1983) 1.38
Calcitonin gene-related peptide stimulates cyclic AMP formation in rat aortic smooth muscle cells. Biochem Biophys Res Commun (1985) 1.38
Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem (1999) 1.38
Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum (2000) 1.37
Human renal carcinoma expresses two messages encoding a parathyroid hormone-like peptide: evidence for the alternative splicing of a single-copy gene. Proc Natl Acad Sci U S A (1988) 1.36
Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein. Endocrinology (1993) 1.35
Prostaglandin receptor EP(4) mediates the bone anabolic effects of PGE(2). Mol Pharmacol (2001) 1.35
The effect of hemopoietic growth factors on the generation of osteoclast-like cells in mouse bone marrow cultures. Endocrinology (1990) 1.32
Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor. J Biol Chem (1988) 1.32
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone (2001) 1.32
Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res (1996) 1.31
Structure of the 5' flanking region of the gene encoding human parathyroid-hormone-related protein (PTHrP). Gene (1989) 1.31
Calcitonin receptor antibodies in the identification of osteoclasts. Bone (1999) 1.29
Functional properties of hormonally responsive cultured normal and malignant rat osteoblastic cells. Endocrinology (1981) 1.29
Msx-2/Hox 8.1: a transcriptional regulator of the rat osteocalcin promoter. Mol Endocrinol (1994) 1.29
Parathyroid hormone-related protein: immunohistochemical localization in cancers and in normal skin. J Bone Miner Res (1989) 1.28
Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem (2001) 1.28
Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone (1996) 1.26
Pattern of gene expression following rat tibial marrow ablation. J Bone Miner Res (1993) 1.25
Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J Bone Miner Res (2000) 1.25
Properties of a calcitonin receptor and adenylate cyclase in BEN cells, a human cancer cell line. Cancer Res (1980) 1.24
Importin beta recognizes parathyroid hormone-related protein with high affinity and mediates its nuclear import in the absence of importin alpha. J Biol Chem (1999) 1.24
Characterization of the rat osteocalcin gene: stimulation of promoter activity by 1,25-dihydroxyvitamin D3. Biochemistry (1988) 1.24
The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med (1996) 1.24
Insulin inhibition of protein degradation in cell monolayers. J Cell Physiol (1980) 1.23
1,25-dihydroxyvitamin-D-receptor in breast cancer cells. Lancet (1980) 1.22
Type beta transforming growth factor (TGF beta) regulation of alkaline phosphatase expression and other phenotype-related mRNAs in osteoblastic rat osteosarcoma cells. J Cell Physiol (1987) 1.22
Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci (2000) 1.22
Integrins and signaling in osteoclast function. Matrix Biol (2000) 1.21
Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone (2010) 1.21
Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3. Endocrinology (1990) 1.21
The alphavbeta3 integrin regulates alpha5beta1-mediated cell migration toward fibronectin. J Biol Chem (1997) 1.20
Glucocorticoid regulation of alkaline phosphatase in the osteoblastic osteosarcoma cell line ROS 17/2.8. Endocrinology (1985) 1.20
Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. J Cell Physiol (1993) 1.18
Calcitonin. Curr Med Chem (1999) 1.18
Osteopenia in the immobilized rat hind limb is associated with increased bone resorption and decreased bone formation. Bone (1989) 1.18
Phosphaturic effect of thyrocalcitonin. Lancet (1966) 1.17
Parathyroid hormone-related protein and hypercalcemia. Cancer (1997) 1.17
PC8 [corrected], a new member of the convertase family. Biochem J (1996) 1.16
Regulation by calcitonin and glucocorticoids of calcitonin receptor gene expression in mouse osteoclasts. Endocrinology (1997) 1.16
Convergence of alpha(v)beta(3) integrin- and macrophage colony stimulating factor-mediated signals on phospholipase Cgamma in prefusion osteoclasts. J Cell Biol (2001) 1.15